Andrew Strahs

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine · 2016 · 738 citations · Full text

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef et al. · Journal of Clinical Oncology · 2009 · 639 citations

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen et al. · Journal of Clinical Oncology · 2013 · 438 citations · Full text

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Antonio C. Wolff, Ann Lazar, Igor Bondarenko et al. · Journal of Clinical Oncology · 2012 · 272 citations · Full text